Skip to main content

MIM Fertility’s AI-powered EMBRYOAID® Now Available with Hamilton Thorne Laser Systems

Hamilton Thorne, Inc. announced a partnership with MIM Fertility, a pioneer provider of AI solutions for the IVF sector.

MIM Fertility

Thanks to this strategic collaboration, the MIM Fertility’s AI-powered embryo assessment tool, EMBRYOAID®, will be available on Hamilton Thorne’s LYKOS® laser systems, offering fertility specialists a powerful combined tool to optimize patient outcomes in assisted reproductive technology (ART).

With this collaboration, MIM Fertility’s advanced AI technology for embryo assessment can now be seamlessly used alongside Hamilton Thorne’s precision laser systems, bringing advanced insights for embryology specialists while assessing the embryos with the highest potential for implantation.

Ula Sankowska, CEO of MIM Fertility, emphasized the value of combining expertise from different areas of the fertility treatment process: “Hamilton Thorne Inc. and MIM Fertility share a common goal of making fertility treatments more effective, accessible, and less stressful for patients. Through this collaboration, we hope to create a powerful ecosystem where AI and laser technology work seamlessly together to provide optimal outcomes.”

“One of Hamilton Thorne’s core values is being customer-focused and collaborative. We are dedicated to delivering significant advancements in assisted reproductive technologies to our customers. Our collaboration with MIM Fertility exemplifies this commitment. Their excellent product, when combined with ours, creates an ideal solution for our customers”. Commented, Eduard Sanchez, Vice President of Research and Development Hamilton Thorne Inc.

About MIM

MIM Fertility specializes in developing human-centered artificial intelligence to enhance the workflow of fertility clinics while equipping fertility specialists with real-time data insights. Their tools help specialists save time, improve efficiency, and improve outcomes. Through top-level partnerships with leading physicians and clinics worldwide, MIM Fertility is committed to delivering impactful advancements to the ART sector. Founded in 2019, the company has received multiple awards, EU medical research grants, and venture capital investment from Tangent Line and Peleton.